152 related articles for article (PubMed ID: 31796225)
1. A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
Mallory RM; Nyborg A; Kalyani RN; Yuan Y; Block SL; Dubovsky F
Vaccine; 2020 Jan; 38(5):1001-1008. PubMed ID: 31796225
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh.
Lewis KDC; Ortiz JR; Rahman MZ; Levine MZ; Rudenko L; Wright PF; Katz JM; Dally L; Rahman M; Isakova-Sivak I; Ilyushina NA; Matyushenko V; Fry AM; Lindstrom SE; Bresee JS; Brooks WA; Neuzil KM
Clin Infect Dis; 2019 Aug; 69(5):777-785. PubMed ID: 30481272
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.
Mallory RM; Malkin E; Ambrose CS; Bellamy T; Shi L; Yi T; Jones T; Kemble G; Dubovsky F
PLoS One; 2010 Oct; 5(10):e13755. PubMed ID: 21060780
[TBL] [Abstract][Full Text] [Related]
4. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.
Curtis D; Ning MF; Armon C; Li S; Weinberg A
Vaccine; 2015 Sep; 33(38):4790-7. PubMed ID: 26241950
[TBL] [Abstract][Full Text] [Related]
7. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Mallory RM; Yi T; Ambrose CS
Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
Sheldon EA; Jeanfreau R; Sliman JA; Charenkavanich S; Rousculp MD; Dubovsky F; Mallory RM
Influenza Other Respir Viruses; 2013 Nov; 7(6):1142-50. PubMed ID: 23061976
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study.
Lindsey BB; Jagne YJ; Armitage EP; Singanayagam A; Sallah HJ; Drammeh S; Senghore E; Mohammed NI; Jeffries D; Höschler K; Tregoning JS; Meijer A; Clarke E; Dong T; Barclay W; Kampmann B; de Silva TI
Lancet Respir Med; 2019 Aug; 7(8):665-676. PubMed ID: 31235405
[TBL] [Abstract][Full Text] [Related]
11. Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
Hoschler K; Maharjan S; Whitaker H; Southern J; Okai B; Baldevarona J; Turner PJ; Andrews NJ; Miller E; Zambon M
Vaccine; 2020 Mar; 38(12):2660-2670. PubMed ID: 32070679
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
Block SL; Falloon J; Hirschfield JA; Krilov LR; Dubovsky F; Yi T; Belshe RB
Pediatr Infect Dis J; 2012 Jul; 31(7):745-51. PubMed ID: 22466322
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children.
Brickley EB; Wright PF; Khalenkov A; Neuzil KM; Ortiz JR; Rudenko L; Levine MZ; Katz JM; Brooks WA
Clin Infect Dis; 2019 Aug; 69(5):786-794. PubMed ID: 30481269
[TBL] [Abstract][Full Text] [Related]
14. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
[TBL] [Abstract][Full Text] [Related]
15. Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016-2017 and 2017-2018 Influenza Seasons in the United Kingdom.
Jackson D; Pitcher M; Hudson C; Andrews N; Southern J; Ellis J; Höschler K; Pebody R; Turner PJ; Miller E; Zambon M
Clin Infect Dis; 2020 Jun; 70(12):2505-2513. PubMed ID: 31642899
[TBL] [Abstract][Full Text] [Related]
16. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.
Cole ME; Kundu R; Abdulla AF; Andrews N; Hoschler K; Southern J; Jackson D; Miller E; Zambon M; Turner PJ; Tregoning JS
Clin Exp Immunol; 2021 Apr; 204(1):125-133. PubMed ID: 33314126
[TBL] [Abstract][Full Text] [Related]
18. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
